Tharimmune, Inc. Common Stock
Symbol: THAR (NASDAQ)
3.07
▲ (9.86%) 0.275
Company Description:
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
Key Stats
- Today's Open: $2.81
- Today's High: $3.445
- Today's Low: $2.81
- Today's Volume: 1.82M
- Yesterday Close: $2.79
- Yesterday High: $3.14
- Yesterday Low: $2.75
- Yesterday Volume: 991.91K
- Last Min Volume: 329
- Last Min High: $3.065
- Last Min Low: $3.065
- Last Min VWAP: $3.065
Company Profile
- Name: Tharimmune, Inc. Common Stock
- Website: https://www.hillstreambio.com
- Listed Date: 2022-01-12
- Location: BRIDGEWATER, NJ
- Market Status: Active
- CIK Number: 0001861657
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $15.80M
- Round Lot: 100
- Outstanding Shares: 5.34M
- Asset Type: CS
RECENT FILINGS FOR THAR
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-08 | PRE 14A | View |
| 2025-09-08 | 8-K | View |
| 2025-09-05 | 8-K | View |
| 2025-09-05 | 8-K | View |
| 2025-09-04 | EFFECT | View |
| 2025-09-03 | S-3/A | View |
| 2025-08-29 | 3 | View |
| 2025-08-27 | 424B5 | View |
| 2025-08-26 | S-3 | View |
| 2025-08-26 | 8-K/A | View |
| 2025-08-26 | 8-K | View |
| 2025-08-22 | 3 | View |
| 2025-08-22 | 3 | View |
| 2025-08-20 | 3 | View |
| 2025-08-20 | 3 | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-08-06 | 4 | View |
| 2025-08-06 | 4 | View |
| 2025-07-31 | 8-K | View |
Latest News on THAR